No, there are extensive third-party CoAs done on the supplements that should be recommended (like OmegaVia). The CoAs are publicly available. At the very least, physicians should educate themselves and allow that knowledge to better help them on recommending what treatment to take for their patients.
If you are vitamin D or iron deficient, simply purchase a well regarded vit D or iron supplement from a company with a publicly available CoA. If you would be benefited by 4 g/d EPA, take OmegaVia EPA 500 in the better absorbed rTG form, not dependent upon being consumed with high fat meal for absorption, held to higher standards than USP-NF (regulates Vascepa) on PV and p-AV (TOTOX), and is manufactured in FDA CGMP regulated facilities. Get more consistently absorbed EPA, save a lot of money (1/7th the cost), and don’t have to worry about potential long term deleterious effects of fatty acid ethyl esters, which have been implicated in organ insult.
As stated to bfost, it should be thought of more like a generic drug. What matters is the API and getting that into your bloodstream. Once you know a certain amount of API has an effect via outcomes studies, you only need to prove you are getting the API. OmegaVia gives you the API (EPA), and even better and more consistently than Vascepa. In fact if they could make Vascepa over again (developed in the 1990s) today, and IP weren’t an issue, they would probably make it just like OmegaVia EPA. Because, frankly, it’s better.
This is also why Matinas Biopharma is a real threat to Amarin—if AMRN makes it far enough that it will mater.
Regards,
-MRC
News 
Market Data 
Discover 
